Appointment of Zeus Capital as Joint Broker
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes
LONDON and PHILADELPHIA - June 30, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces
the appointment of Zeus Capital as a joint broker to the Company with immediate effect.
Peel Hunt and Panmure Liberum both continue in their respective roles as NOMAD and Joint Broker and Joint Broker to the Company.
Related Party Transaction
Richard Hughes, a Director of the Company, is an associate of Zeus Capital as defined under the AIM Rules. Zeus Capital is therefore a related party of the Company pursuant to the AIM Rules and the appointment of Zeus Capital including a £75,000 annual retainer due to Zeus Capital is a related party transaction. The Directors (other than Richard Hughes who is an associate of Zeus Capital) consider, having consulted with the Company's nominated adviser Peel Hunt, that the appointment of Zeus Capital including the annual retainer are fair and reasonable insofar as Shareholders are concerned.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.